PartnershipPress releaseWeHealth by Servier

WeHealth by Servier and MobioSense form a partnership to develop digital portable heart attack detection test

By November 29, 2018 No Comments

About acute chest pain and Acute Myocardial Infarction (AMI)

Complaint of chest pain is one of the leading causes of visits to the emergency room worldwide. Only 10% of them are true heart attack patients, but 60% of them end up staying in hospital for more than 12 hours.

When patients experience chest pain, physicians must take a chain of medical decision to diagnose several forms of AMI and instable angina, based on ECG, clinical symptoms, and troponin tests.
Cardiac troponin I is a gold standard biomarker of heart attack. High sensitivity detection of troponin allows an earlier detection and lead physicians to take better actions right away for the patient.

About High Sensitive Troponin (hs-cTnI) test for heart attack detection

Current protocols to rule out heart attacks can take up to 12 hours to complete due to the lower sensitivity of conventional troponin tests, a gold standard tests for identifying heart attacks, and also due to lack of portability requiring tests to be done at a hospital with central lab, mandating overnight stays at the emergency room for almost all chest pain patients regardless of final diagnosis, and leading to overcrowding and patient stress, especially for the ~90% of chest pain patients who don’t have ultimately cardiac issues.
“Serum troponin is an exquisitely sensitive marker of myocardial injury and is necessary for establishing the diagnosis of myocardial infarction. High-sensitivity troponin assays are improving the diagnostic accuracy, and rapid detection of myocardial infarction. The early identification of MI is vital for the prompt institution of anti-thrombotic therapy to limit myocardial damage, and preserve cardiac function.” (Melissa A Daubert and Allen Jeremias, Vasc Health Risk Manag. 2010; 6: 691–699)

About the digital diagnostic Solution

Mobiosense is developing a digital portable blood diagnostic platform based on its patented semiconductor biosensor, which utilizes the principles of Field Effect Transistors (FETs) to enable direct electrical measurements of biomolecules without intermediary biochemical reactions, providing a highly sensitive yet robust label-free method of biomarker detection, a significant technical advancement in the point of care diagnostic market by providing both sensitivity and portability unlike traditional optical, and electrochemical methods.